Inhibitors of PDE have shown promise for augmenting current therapy, both for chemotherapy and for radiotherapy, by elevating levels of oxygen in the tumor, reducing drug resistance, and elevating drug sensitivities. The gene discussed is ALDH7A1; the disease is neoplasm.